Jane Street Group, LLC Blueprint Medicines Corp Call Options Transaction History

Jane Street Group, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$84.1 - $120.5 $116 Million - $166 Million	1,381,500 New	1,381,500 $128 Million
Q1 2022 May 17, 2022	BUY	$54.1 - $110.08 $979,210 - $1.99 Million	18,100 Added 420.93%	22,400 $1.43 Million
Q4 2021 Feb 15, 2022	BUY	$94.25 - $115.99 $141,375 - $173,985	1,500 Added 53.57%	4,300 $461,000
Q3 2021 Nov 16, 2021	SELL	$80.98 - $109.47 $2.02 Million - $2.73 Million	-24,900 Reduced 89.89%	2,800 $288,000
Q2 2021 Aug 16, 2021	BUY	$82.78 - $101.0 $322,842 - $393,900	3,900 Added 16.39%	27,700 $2.44 Million
Q1 2021 May 18, 2021	SELL	$90.71 - $108.28 $108,851 - $129,936	-1,200 Reduced 4.8%	23,800 $2.31 Million
Q4 2020 Feb 17, 2021	BUY	$92.08 - $124.48 $662,976 - $896,256	7,200 Added 40.45%	25,000 $2.8 Million
Q3 2020 Nov 17, 2020	SELL	$66.45 - $92.7 $1.92 Million - $2.68 Million	-28,900 Reduced 61.88%	17,800 $1.65 Million
Q2 2020 Aug 17, 2020	BUY	$57.09 - $79.27 $1.31 Million - $1.82 Million	22,900 Added 96.22%	46,700 $3.64 Million
Q1 2020 May 15, 2020	BUY	$48.11 - $82.22 $1.15 Million - $1.96 Million	23,800 New	23,800 $1.39 Million

350

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $6.57B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.